Compare · CDXC vs DFTX
CDXC vs DFTX
Side-by-side comparison of ChromaDex Corporation (CDXC) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXC and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 34.0x CDXC ($176.9M).
- DFTX has hit the wire 16 times in the past 4 weeks while CDXC has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 5 for CDXC).
- Company
- ChromaDex Corporation
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $176.9M
- $6.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 16
- Recent ratings
- 5
- 7
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
Latest DFTX
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits